logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Antimetabolite Immunosuppressant class drugs

    FiltersReset Filters
    3 results

    • mycophenolic acid

      (mycophenilic acid)
      Archis Pharma LLC
      Usage: Mycophenolic acid delayed-release tablets are indicated for the prophylaxis of organ rejection in kidney transplant patients, both adult and pediatric (5 years and older), in combination with cyclosporine and corticosteroids. Use interchangeably with mycophenolate mofetil is not recommended without physician supervision.

    • mycophenolic acid

      (MYCOPHENOLIC ACID)
      Ascend Laboratories, LLC
      Usage: Mycophenolic acid delayed-release tablets are indicated for the prophylaxis of organ rejection in adults and pediatric patients (5 years and older) following kidney transplant, to be used in combination with cyclosporine and corticosteroids. Interchangeability with mycophenolate mofetil requires physician supervision due to absorption differences.

    • myfortic

      (mycophenolic acid)
      Novartis Pharmaceuticals Corporation
      Usage: Myfortic (mycophenolic acid) is indicated for the prophylaxis of organ rejection in adult and pediatric kidney transplant patients (5 years and older, at least 6 months post-transplant), to be used alongside cyclosporine and corticosteroids. Use caution as it should not be interchangeable with mycophenolate mofetil without physician supervision.